Andrew Taylor and Nick Warren have contributed the foreword to e-Competitions’ latest special issue on healthcare. The article reviews a wide range of antitrust and merger cases in the European health sector in recent years, and identifies several common themes. These include the tension between the application of competition law to suppliers of healthcare services…
Last month NHS England and NHS Improvement (NHS E/I) published plans for a new approach to assessing NHS transactions that put more emphasis on ensuring local populations benefit from NHS mergers. Until recently, NHS transactions were overseen by NHS Improvement for organisational impacts (e.g. finance, organisational risk), and the Competition & Markets Authority (CMA) for competition….
Combination therapies use two or more drugs as part of a single treatment regime for an increasing number of diseases, such as cancer. Combination treatments can deliver better outcomes for patients by targeting a disease via multiple pathways or at multiple levels. Unfortunately, there are a number of barriers to making combination therapies more widely…
Andrew Taylor, a partner at Aldwych Partners, has written for the Health Service Journal (HSJ) this week on how efforts to clear the elective care backlog are likely to feed into higher clinician labour costs, even without a national pay rise. Clinicians willing to work extra time are likely to gravitate to those opportunities where…
While the NHS will get much of the money from the new Health & Social Care Levy in the next three years, yesterday’s Health Service Journal (HSJ) reported that senior NHS management expect it to be unable to deliver many of the goals in 2019’s Long Term Plan. A fundamental problem for the NHS is…
Guides, White Papers & Research
Buy-and-Build Strategies: Managing the risk of UK Competition and Markets Authority intervention
This paper draws on our experience as former competition regulators, and our research on buy-and-builds, to identify opportunities that can mitigate the risk of CMA intervention for these platforms.
It contains practical advice around:
- The likelihood of deals being called-in by the CMA
- Influencing the CMA’s view of a market
- How to best engage with the CMA
- Drivers of CMA review costs
Fill in your details to receive your copy:
We will never share your details with anyone.